Interstitial cystitis (also called bladder pain syndrome) has no single cure, but treatment options have expanded significantly in recent years. The current approach uses a tiered system, starting with the least invasive options and moving toward more advanced therapies only when simpler ones fall short. What’s changed most recently is a growing emphasis on personalized treatment based on your specific symptom pattern, plus early-stage research into stem cell therapy that shows real promise for repairing bladder damage.
How Treatment Is Structured Today
The American Urological Association organizes interstitial cystitis treatment into six tiers, from least to most invasive. The guiding principle is straightforward: start conservative, and escalate only when your quality of life isn’t improving. Because no single treatment works for a majority of patients, finding the right combination often requires working through several options. Surgical treatment is reserved as a last resort, appropriate only after other alternatives have been exhausted, with one exception: if a doctor identifies Hunner lesions (inflammatory patches on the bladder wall), those can be treated directly at any stage.
First and Second Line: The Foundation
Every treatment plan begins with education and lifestyle changes. This means learning your personal triggers, practicing stress management (since stress reliably worsens symptoms), and adjusting daily habits. Diet plays a significant role for many people. The most commonly reported food and drink triggers include citrus juices, coffee, tea, soda, alcohol, tomatoes and tomato-based sauces, spicy foods, chocolate, artificial sweeteners, and foods containing MSG. An elimination diet, where you remove these items and reintroduce them one at a time, is the standard way to identify which ones affect you.
If lifestyle changes alone aren’t enough, second-line treatment adds pelvic floor physical therapy and oral medications. Physical therapy focuses on releasing tight muscles, trigger points, and connective tissue restrictions in the pelvic region. Importantly, Kegel exercises (pelvic floor strengthening) should be avoided, as they can make symptoms worse. For oral medications, the main options include amitriptyline (a low-dose antidepressant that reduces bladder pain), hydroxyzine (an antihistamine), and cimetidine (an acid-reducing medication). Pain management at this stage typically combines medication with stress reduction and manual therapy.
The Concern With Pentosan Polysulfate
Pentosan polysulfate sodium has been used for decades as the only oral medication specifically approved for interstitial cystitis, but safety concerns have changed how it’s prescribed. Research has linked long-term use to a form of eye damage affecting the macula, the part of the retina responsible for sharp central vision. The risk climbs with cumulative exposure: about 13% of patients who take between 500 and 1,000 grams over their lifetime develop macular changes, and that rate jumps to 50% among those exceeding 1,500 grams. Annual eye screening is now recommended once you reach a cumulative dose of 500 grams. This damage can be irreversible, so many clinicians and patients are weighing the benefits more carefully than in the past.
Bladder Instillations for Flares and Ongoing Pain
When oral treatments aren’t providing enough relief, a common next step is instilling medication directly into the bladder through a catheter. The most widely used “cocktail” combines lidocaine (a numbing agent), heparin, and sodium bicarbonate. In a controlled trial, this combination reduced pain by 42% over 12 hours compared to 21% with placebo. Half of patients receiving the active treatment reported at least 50% overall improvement, versus only 13% on placebo. The relief is temporary, lasting roughly 12 hours per treatment, but regular instillations (weekly or twice weekly) can help manage ongoing symptoms or acute flares.
A sustained-release lidocaine device (LiRIS) has been tested in early trials. The small device sits inside the bladder and releases lidocaine continuously over two weeks, eliminating the need for repeated catheterizations. It completed a Phase 1 trial showing good tolerability, but it has not yet reached widespread clinical availability.
Nerve Stimulation Therapies
Neuromodulation, which uses electrical signals to calm overactive nerve pathways, has become an increasingly important option for people who don’t respond to medications or instillations.
Percutaneous tibial nerve stimulation (PTNS) involves placing a thin needle near the ankle and sending mild electrical pulses to the tibial nerve, which shares a pathway with the nerves controlling bladder function. It requires weekly outpatient visits, and adherence can be challenging. In clinical studies, about 70% of patients reported some degree of symptom improvement, with significant reductions in daytime urinary frequency (averaging nearly 4 fewer voids per day) and urgency episodes. About 48% of patients successfully transitioned to a less frequent maintenance schedule. Pain improvement was observed but was not always statistically significant.
Sacral neuromodulation takes a more direct approach, implanting a small device near the base of the spine that delivers continuous electrical stimulation to the sacral nerves. It’s typically considered after tibial nerve stimulation has been tried. In testing, about 63% of interstitial cystitis patients responded well enough to proceed with a permanent implant. Those who received the implant experienced an average reduction of nearly 5 points on a 10-point pain scale. Sacral neuromodulation is included in both American and European urology guidelines but has not yet received specific regulatory approval for interstitial cystitis from the FDA or its European counterpart.
Botox Injections Into the Bladder
Injecting botulinum toxin A directly into the bladder wall is another option for refractory cases. In a controlled trial, 63% of patients receiving Botox reported improvement compared to 15% on placebo. The effect is temporary: most patients experience symptom relief for six to nine months before symptoms return. Some studies show more modest results, with about 38% still improved at six months and only 21% at twelve months. Repeated injections appear to maintain effectiveness over time, but the need for repeat procedures every several months is a significant commitment.
Phenotyping: Matching Treatment to Your Symptoms
One of the most meaningful shifts in interstitial cystitis care is the move toward clinical phenotyping, essentially classifying patients based on their specific symptom patterns rather than treating everyone the same way. The UPOINT system categorizes patients across domains including urinary symptoms, pelvic organ involvement, infection history, neurological factors, and muscle tenderness. Each domain points toward a different treatment strategy.
This matters because studies using phenotype-guided treatment have shown better outcomes than the older approach of prescribing the same medications to all patients. For example, amitriptyline has historically shown inconsistent results in broad studies, but when given specifically to patients whose symptom profile suggests it would help, the response rates improve. The logic is intuitive: interstitial cystitis likely has multiple underlying causes, and a treatment targeting the wrong mechanism won’t work regardless of how effective it is for the right patient.
Stem Cell Therapy: Early but Promising
The newest development generating attention is stem cell therapy aimed at actually repairing bladder damage rather than just managing symptoms. A Phase 1/2a trial tested mesenchymal stem cells (derived from human embryonic stem cells) in 22 patients with interstitial cystitis. The safety profile was encouraging: no serious drug-related side effects were observed, and the mild adverse events that occurred, such as temporary bladder discomfort, resolved on their own.
The most striking finding was structural. Eight out of 12 patients receiving the stem cell treatment showed reduction or complete resolution of Hunner lesions at six months, compared to no meaningful change in the placebo group. Preclinical research suggests these stem cells may work by differentiating into the types of cells that form the bladder lining, potentially restoring the protective barrier that breaks down in interstitial cystitis. This is still early-stage research with small patient numbers, but it represents a fundamentally different approach: regeneration rather than symptom suppression. Larger trials will be needed to confirm these results and establish who would benefit most.